The CJC-1295 / Ipamorelin blend pairs two growth-hormone secretagogues that act on different receptors. It is studied in research for how the two work together to influence the body’s own growth-hormone release. Both are research-use-only compounds — not approved for human use.
- CJC-1295: a GHRH analogue that activates the GHRH receptor.
- Ipamorelin: a selective peptide that activates the ghrelin receptor (GHS-R1a).
- Why combine: the two receptors drive GH release through complementary pathways.
- Status: not FDA-approved; research use only.
What is the CJC-1295 / Ipamorelin blend?
Growth-hormone release is governed by two main signals: GHRH and ghrelin. This blend pairs one peptide for each pathway — CJC-1295 (GHRH side) and Ipamorelin (ghrelin/GHS side) — which is why researchers study them together rather than separately.
| CJC-1295 | Ipamorelin | |
|---|---|---|
| Class | GHRH analogue | GHRP / ghrelin-receptor agonist |
| Receptor | GHRH receptor | GHS-R1a |
| Noted in research for | Sustained GHRH signaling | Selective GH release |
Why they are studied together
Because the GHRH and ghrelin pathways are distinct, activating both at once is of mechanistic interest. In secretagogue research, combining a GHRH analogue with a GHRP-class peptide has been reported to produce substantially greater growth-hormone release than either class alone at matched doses — the main reason the two are paired.
- Two-pathway activation — GHRH receptor (CJC-1295) plus GHS-R1a (Ipamorelin).
- Selectivity — Ipamorelin is noted in research for releasing GH without strongly affecting cortisol or prolactin.
- Pulsatility — the combination is studied for influencing the natural rhythm of GH release.
Related compounds
For a single-peptide GHRH analogue, see our overview of Tesamorelin. New to the category? Start with What Are Research Peptides?
Storage & handling
The blend is supplied lyophilized. Keep it cold and dark, reconstitute only when needed for research, and limit freeze–thaw cycles. See our guide on reconstituting lyophilized peptides.
Research status
CJC-1295 and Ipamorelin are not approved by the FDA for human use; the available evidence is largely preclinical. Treat the blend strictly as a research compound.
Looking for the research-grade CJC-1295 / Ipamorelin blend?
Lab-tested, with third-party purity verification.